We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Becton Dickinson and Company | NYSE:BDX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.08 | -0.46% | 233.52 | 235.76 | 232.46 | 234.03 | 875,385 | 17:17:17 |
From May 2019 to May 2024
By Colin Kellaher
Becton Dickinson & Co. Wednesday said the U.S. Department of Health & Human Services will use its products to expand access to rapid point-of-care testing for Covid-19.
The Franklin Lakes, N.J., medical-technology company said HHS has committed to buy 2,000 BD Veritor Plus Systems, along with 750,000 SARS-CoV-2 antigen test kits, in a bid to expand testing through a broad, decentralized network.
Becton Dickinson said distribution will begin next week.
The U.S. Food and Drug Administration earlier this month granted Becton Dickinson an emergency-use authorization for the BD Veritor Plus System for rapid detection of SARS-CoV-2.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 15, 2020 07:32 ET (11:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Becton Dickinson Chart |
1 Month Becton Dickinson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
